Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.

Heavey et al. (2000) ran a small crossover trial. Each child got placebo, low-dose methylphenidate, and high-dose methylphenidate in random order. No one knew which pill was which. Thirteen autistic children with ADHD symptoms took part.

Doses were 0.3 mg/kg and 0.6 mg/kg, given twice a day. The team watched for hyperactivity, stereotypy, and side effects.

Eight of the thirteen kids were clear responders on the 0.3 mg dose. Hyperactivity and some stereotypic behaviors dropped. The 0.6 mg dose added little benefit.

Side effects jumped at the higher dose. Irritability and social withdrawal were common. One child had to stop.

Dawson et al. (2000) review puts the finding in context. It says psychostimulants, antipsychotics, and naltrexone all have the best evidence for cutting autism hyperactivity. The review includes this very trial, showing the field already saw promise in stimulants.

Fovel et al. (1989) used the same double-blind crossover design with haloperidol. Both studies show medicines can tame tough behaviors, but learning gains are not guaranteed.

Stancliffe et al. (2007) later tested risperidone for irritability, not hyperactivity. Their clean RCT design mirrors L et al., giving clinicians two separate drug paths for different autism symptoms.

If you have an autistic client who cannot sit still, low-dose methylphenidate is worth a try. Start at 0.3 mg/kg, watch for irritability, and stop if social withdrawal shows up. Document behavior daily so you can spot the small but real gains this study promises.